You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Breast Cancer Articles
Popular Breast Cancer Articles
Highly Recommended Breast Cancer Articles
Send a link to this page to your friends and colleagues.
Metformin Lowers Breast Cancer Risk
Metformin is the aspirin of the diabetes world, an almost-wonder drug that proves itself again and again the longer it's around. This time, a new study shows that postmenopausal women with diabetes who have taken metformin for several years are 25 percent less likely to develop breast cancer than nondiabetic women.
The study, conducted by the UCLA David Geffen School of Medicine, analyzed data on 68,000 postmenopausal women who had participated in the Women's Health Initiative, a massive 15-year federal study of women past childbearing age.
The researchers found that women who had taken metformin for more than a decade had a statistically significant lower risk of invasive breast cancer than women who did not have diabetes. They also found that women with diabetes who took drugs other than metformin ran a slightly higher risk of developing breast cancer than their nondiabetic peers.
The UCLA study joins other research suggesting that metformin may have anti-cancer properties, including capabilities against pancreatic cancer. Why the drug reduces the risk of cancer is unclear. One possibility is that metformin increases the activity of AMP-kinase, an enzyme that detects cellular energy levels and may be able to cause cancer cells to self-destruct.
The researchers reported that the 25 percent lower risk figure took into account such factors as body mass index, exercise level, and mammogram frequency, all of which affect breast cancer risk.
Because the new study does not establish a cause-and-effect link between taking metformin and lowered breast cancer risk, the National Cancer Institute will be sponsoring a five-year trial in which nondiabetic women with early breast cancer will receive either metformin or a placebo over the study's duration.
The study was published in the Journal of Clinical Oncology.
Source: MyHealthNewsDaily
Categories: Breast Cancer, Diabetes, Diabetes Health, Metformin, Research
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...